On the recordJuly 24, 2018
Cures requires the Food and Drug Administration to evaluate its trial designs and issue guidance for the purposes of 'incorporating complex adaptive and other novel trial designs.'
Source
congress.govMichael Burgess: “Cures requires the Food and Drug Administration to evaluate its trial designs and issue guidance for the purposes of…”
Editor's note · Context
Emphasizing the need for FDA to adapt trial designs.
Share
More from Michael Burgess
Nov 14, 2023
For the purpose of debate only, I yield the customary 30 minutes to the Congresswoman from Pennsylvania (Ms. Scanlon), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is…
Jan 30, 2024
I am pleased to yield 4 minutes to the gentleman from Missouri (Mr. Alford) for his comments.
Apr 12, 2024
I thank the gentleman for yielding additional time. However, one-sided pressure by the White House is not the way to ensure that end. Mr. Speaker, I urge passage of this rule from our committee, and I urge passage of the underlying…
Jan 30, 2024
I never expected that CMMI was actually going to deliver the cost savings that was promised.
Other voices in this conversation
